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Background: Stage 2 hypertension often requires combination antihypertensive therapy. 
Ambulatory blood pressure monitoring (ABPM) is a useful tool for assessing antihypertensive 
drugs and their combinations.
Objective: To compare the effect of a moderate dose of angiotensin receptor blocker/calcium 
channel blocker (ARB/CCB) combined with a diuretic versus a maximal dose of ARB with a 
diuretic on 24-hour ambulatory blood pressure monitoring (ABPM) and other derived ambulatory 
blood pressure (ABP) parameters.
Methods: The EXforge As compared to Losartan Treatment ABPM substudy was a randomized, 
double-blind, parallel-group, active-control, forced-titration study of patients with Stage 2 
hypertension that compared the efficacy of initial treatment with valsartan/amlodipine 160/5 mg 
(n = 48) or losartan 100 mg (n = 36). At week 3, hydrochlorothiazide (HCTZ) 25 mg was added 
in both treatment groups. ABP was measured at baseline and at week 6. Additionaly, 24-hour 
ABP, nighttime (10 pm to 6 am) and daytime (6 am to 10 pm) ABP, and ABP load (percentage 
of readings above 140/90 mmHg) were determined.
Results: Eighty-four patients (48 ARB/CCB/HCTZ, 36 ARB/HCTZ) had ABPM at base-
line and at week 6. Reductions of systolic/diastolic ABP were greater in the ARB/CCB/
HCTZ group than in the ARB/HCTZ group for 24-hour mean ABP (-22.0/-13.3 versus 
-17.4/-8.1 mmHg), as well as nighttime ABP (-22.2/-13.3 versus -16.2/-7.4 mmHg), daytime 
ABP (-21.9/-13.0 versus -18.1/-8.6 mmHg), ABP in the last 4 hours of the dosing period 
(-21.5/-13.5 versus -17.0/-7.7 mmHg), and ABP load (21.7%/12.8% versus 30.8%/20.0%).
Conclusion: Initiating antihypertensive treatment with moderate doses of ARB/CCB with a 
diuretic is more effective in lowering nighttime and daytime ABP and reducing ABP load than 
a maximal dose of an ARB with a diuretic.
Keywords: antihypertensive drugs, ambulatory blood pressure, ambulatory blood pressure 
monitoring, combination therapy, valsartan, amlodipine, hydrochlorothiazide, losartan
Background
There is overwhelming evidence that ambulatory blood pressure (ABP) monitoring 
(ABPM) is better at predicting future risk for cardiovascular morbidity and mortality 
compared with usual office blood pressure (BP) measurements in both untreated and 
treated hypertensive patients.1–4 The BP load, defined as the percentage of readings 
in 24-hour ABP in which BP is above 140/90 mmHg, has also been shown to predict 
target organ damage in patients with arterial hypertension.5,6 ABPM is a useful tool 
for studying antihypertensive drugs and their combinations and provides greater Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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insight into circadian BP variation than does clinic BP 
monitoring. Other clinically important features of ABPM 
are its ability to assess the capacity of a given antihyper-
tensive treatment to adequately control BP throughout the 
24-hour dosing period, and to provide information on the 
possible need to differentiate dosing times of different   
drugs.7,8
Among patients with Stage 2 hypertension, the 
combination of two or more agents is recommended as initial 
treatment to achieve BP control.9–11 Many renin-angiotensin 
II-aldosterone system (RAAS)-based single-pill combinations 
include either an angiotensin-converting-enzyme (ACE) 
inhibitor or an angiotensin receptor blocker (ARB) with a 
diuretic (eg, hydrochlorothiazide [HCTZ]), or an ACE inhibi-
tor or ARB with a calcium-channel blocker (CCB). RAAS/
Diuretic and RAAS/CCB combinations have fully additive 
BP-lowering effects.11 However, based on findings from 
the Avoiding Cardiovascular Events through Combination 
Therapy in Patients Living with Systolic Hypertension study, 
a RAAS/CCB combination may control BP more effectively 
and reduce cardiovascular morbidity and mortality, as com-
pared with a RAAS/diuretic combination.12,13
The additional BP reduction that results from combining 
antihypertensive agents from two different classes is approxi-
mately five times greater than would result from doubling 
the dose of a single antihypertensive agent.14 Thus, it was 
hypothesized that a triple-therapy combination of moderate 
doses of an ARB and a CCB with a diuretic would be more 
effective than a dual-therapy combination of the maximal 
dose of an ARB with a diuretic. Using clinic BP measures, 
the authors reported in the EXforge As compared to Losartan 
Treatment (EXALT) study that early initiation of a triple-
therapy ARB/CCB/HCTZ combination lowered BP more 
effectively than a maximal-dose dual-therapy ARB/HCTZ 
combination in 488 patients with Stage 2 hypertension.15 
ABP outcomes are reported here for the subgroup of patients 
from the EXALT study who had ABPM at baseline and after 
6 weeks of study treatment.
Methods
The design of the EXALT study has been reported in 
full previously.15 It was a randomized, double-blind, 
parallel-group, active-control, forced-titration trial that 
was conducted between July 2009 and January 2010 at 80 
centers in the USA. Twenty centers with capabilities to use 
the ABP device participated in the ABPM substudy. Ethics 
committee and/or institutional review board approval was 
granted at all participating centers, and all patients provided 
written informed consent before enrollment. The study was 
conducted in accordance with the ethical principles of the 
Declaration of Helsinki.
eligibility criteria
Male and female outpatients aged $18 years were enrolled in 
the EXALT study if they had Stage 2 systolic hypertension, 
defined as a mean in-office sitting systolic BP (MSSBP) of 
$160 mmHg and ,200 mmHg at randomization. Patients were 
excluded if they were taking more than three antihypertensive 
medications at study enrollment or if BP was $140/90 mmHg 
while on triple therapy (one therapy of which was a diuretic) 
at the optimal dose of each drug. Other key exclusion crite-
ria were: MSSBP $200 mmHg or mean sitting diastolic BP 
(MSDBP) $110 mmHg at the time of enrollment (ie, prior to 
washout); use of four or more   antihypertensive medications 
in the past 30 days; secondary hypertension; significant heart 
disease (eg, recent stroke/  transient ischemic attack, heart 
failure, coronary artery bypass graft surgery, coronary inter-
vention, unstable angina, myocardial infarction, heart block, 
atrial   fibrillation/flutter, or valve disease); significant renal or 
hepatic   impairment; or baseline serum sodium ,135 mEq/L, 
serum potassium ,3.5 mEq/L or $5.5 mEq/L, or glycosylated 
hemoglobin .9%. Exclusion criteria specific to the ABPM 
substudy were: arm circumference .42 cm, employment 
requiring night-shift work, or a history of sleep apnea.
study design
Study treatment schedules for the EXALT study have 
been presented previously.15 Study treatment in the ABPM 
substudy was force titrated as summarized in Figure 1. After 
screening and a 1- to 2-week washout, eligible patients 
were randomized and initiated treatment with valsartan/
amlodipine 160/5 mg or losartan 100 mg. At week 3, HCTZ 
25 mg was added in both treatment groups. ABPM was 
performed for 24 hours before study visits at baseline and at   
week 6.
Patients were discontinued from the study if they had 
MSSBP $200 mmHg or MSDBP $110 mmHg, or if they 
could not be force titrated to the next dose due to adverse 
events or hypotension (MSSBP ,100 mmHg or MSDBP 
,60 mmHg). Patients took double-blinded study   medication 
once daily, in the morning. On study visit days, clinic BP mea-
sures were obtained before the daily dose of study   medication. 
Patients were not permitted to take other   antihypertensive or 
diuretic treatments during the study.
BP assessments
Patients enrolled in the EXALT study had clinic BP 
measurements at each study visit with an automated digital Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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brachial artery BP device; the full methods for clinic BP 
measurements have been reported previously.15 At the 
20 centers that participated in the ABPM substudy, patients 
who expressed interest in participating in the substudy and 
satisfied the entry criteria were enrolled.
After baseline clinic BP measurement, the ABP device 
(SpaceLabs 90207, Redmond, WA) was placed on the patient’s 
nondominant arm. Readings were correlated with clinic BP 
measurements at the time of device placement. Following the 
correlation procedure, BP and heart rate were recorded every 
20 minutes during the 24-hour monitoring period. Quality-
control criteria for ABPM were defined as starting between 
7 and 10 am, with at least 24 hours of ABP data after the 
beginning of the test time, at least 80% of expected readings 
captured during the 24-hour period, and no more than two 
nonconsecutive hours with no valid BP reading. If baseline 
ABPM was successful, the patient was randomized into the 
ABPM substudy. If baseline ABPM was unsuccessful, their 
randomization was postponed and the ABP device was reap-
plied within 48 hours. If the second ABP measurement was 
successful, the patient was randomized into the study, and 
ABP was measured again at the week-6 study visit. Patients 
who had two unsuccessful attempts to measure mean 24-hour 
ABP at baseline were discontinued from the ABPM substudy 
but were allowed to continue in the main study.
study endpoints
The primary study efficacy variable was the change from 
baseline in MSSBP at week 6 in the overall population, 
as has been reported previously.15 The following efficacy 
endpoints were evaluated for both systolic and diastolic ABP 
in this ABPM substudy: 24-hour ABP, nighttime ABP (10 pm 
to 6 am), daytime ABP (6 am to 10 pm), ABP in the last 
4 hours of the dosing period, and hourly ABP values. ABP 
load was defined as the percentage of systolic ABP readings 
that were .140 mmHg and the percentage of   diastolic ABP 
  readings that were .90 mmHg. Adverse events were recorded 
at each study visit.
statistical analysis
The ABPM substudy population for efficacy and safety 
analyses in this report included all patients with valid ABPM 
at baseline and at week 6. Baseline demographics and 
clinical characteristics were compared between treatment 
groups with a two-sample t-test for continuous variables 
and chi-square or Fisher’s exact test for categorical variables 
(excluding missing values). Patients were analyzed for 
efficacy endpoints according to the treatment they were 
assigned at randomization. The least-squares mean and 
standard error of the mean (SEM) for changes in systolic 
and diastolic ABP from baseline to week 6 were analyzed 
for 24-hour mean ABP, nighttime ABP, daytime ABP, and 
ABP in the last 4 hours of the dosing period. Least-squares 
mean and SEM for changes in clinic BP measures (MSSBP 
and MSDBP) from baseline to week 6 were also analyzed 
for patients participating in the ABPM substudy. Analysis 
of covariance (ANCOVA) with baseline MSSBP and 
treatment regimen as explanatory variables was used to 
6 3 0 −1 −2
Week
Washout
ABPM*
Valsartan 160 mg +
Amlodipine 5 mg
Losartan 100 mg
ABPM*
Forced
Addition
of HCTZ
Valsartan 160 mg +
Amlodipine 5 mg +
HCTZ 25 mg
Losartan 100 mg +
HCTZ 25 mg
Randomization Screening
Figure 1 ABPM substudy design. study medication was force titrated at week 3. ABP was measured for 24 hours before the visits at week 0 and week 6.
Note: *ABPM was conducted for 24 hours prior to the week-0 and week-6 visits.
Abbreviations: ABP, ambulatory blood pressure; ABPM, ambulatory blood pressure monitoring; HcTZ, hydrochlorothiazide.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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test each efficacy endpoint for superiority of the valsartan/
amlodipine group over the losartan group. For ABP load, 
both ANCOVA and a nonparametric Wilcoxon rank-sum 
test were used to determine between-treatment differences. 
Adverse events were coded using Medical Dictionary for 
Regulatory Activities terminology to give a system organ 
class and preferred term for each event.16
Results
Patients
Of the 488 patients enrolled in the EXALT study (241 in the 
valsartan/amlodipine/HCTZ group and 247 in the losartan/
HCTZ group), 416 (85%) completed the study.15 Of the 
114 patients who were enrolled in the ABPM substudy, 
84 patients (36 in the valsartan/amlodipine/HCTZ group 
and 48 in the losartan/HCTZ group), satisfied the eligibility 
criteria and provided valid ABPM data at the baseline visit. 
All 84 of these patients also completed the follow-up ABP 
assessment successfully at week 6. Baseline characteristics 
among the patients in the ABPM substudy were balanced 
between treatment groups (Table 1) and were similar to those 
of the whole study population.15
Efficacy
ABP
Baseline values for 24-hour mean ABP ± standard devia-
tion (SD) were 150.1 ± 15.0/87.5 ± 12.0 mmHg and 
148.1 ± 13.8/86.1 ± 11.4 mmHg in the   valsartan/  amlodipine/
HCTZ  and  losartan/HCTZ  groups,    respectively. 
Least-squares mean ±  SEM  reductions  in  24-hour 
mean ABP at week 6 were significantly greater in the 
valsartan/amlodipine/HCTZ group than in the losar-
tan/HCTZ group (-22.0 ± 1.7/-13.3 ±  1.0  mmHg 
and -17.4 ± 1.5/-8.1 ±  0.8  mmHg,  respectively; 
P = 0.043/P , 0.001; Figure 2). Reductions in nighttime 
ABP (10 pm to 6 am), daytime ABP (6 am to 10 pm), and 
ABP in the last 4 hours of the dosing period (the early morning 
hours prior to the next dose) are shown in Figure 2. At week 6, 
significantly greater reduction in systolic ABP was seen for 
nighttime ABP (10 pm to 6 am) in the valsartan/amlodipine/
HCTZ group compared with the losartan/HCTZ group.
After 6 weeks of treatment, valsartan/amlodipine/HCTZ 
provided greater and more consistent reduction of ABP 
throughout the 24-hour measuring period than losartan/
HCTZ (Figure 3).
Mean values for systolic ABP load (the percentage of 
readings that were .140 mmHg) and diastolic ABP load (the 
percentage of readings that were .90 mmHg) are shown in 
Figure 4. Reduction of systolic ABP load in the valsartan/
amlodipine/HCTZ group (from 70.2% to 21.7%) was greater 
than in the losartan/HCTZ group (from 68.3% to 30.8%; 
ANCOVA, P = 0.062; Wilcoxon, P = 0.025). Reduction of 
diastolic ABP load in the valsartan/amlodipine/HCTZ group 
(from 42.6% to 12.8%) was also greater than in the losartan/
HCTZ group (from 40.0% to 20.0%; ANCOVA, P = 0.032; 
Wilcoxon, P = 0.053).
clinic BP
Among the patients in the ABPM substudy popula-
tion, mean ± SD baseline values for clinic MSSBP/
Table 1 Baseline demographics and characteristics by treatment (ABPM substudy population)
Variable Valsartan/Amlodipine/HCTZ group (n = 36) Losartan/HCTZ group (n = 48) P-value
Age, years, mean ± sD 56.1 ± 8.00 56.0 ± 8.49 0.940
sex, male, n (%) 17 (47.2%) 26 (54.2%) 0.529
Race, n (%) 0.544
  caucasian 15 (41.7%) 26 (54.2%)
  Black 20 (55.6%) 20 (41.7%)
  Asian 1 (2.8%) 1 (2.1%)
  Other 0 1 (2.1%)
Diabetes, n (%) 8 (22.2%) 9 (18.8%) 0.695
Metabolic syndrome,* n (%) 25 (69.4%) 27 (56.3%) 0.263
clinic BP, mmHg, mean ± sD
  MssBP 168.8 ± 6.92 170.5 ± 10.24 0.383
  MsDBP 98.4 ± 8.59 98.3 ± 9.02 0.932
Ambulatory BP, mmHg, mean ± sD
  systolic ABP 150.1 ± 14.95 148.1 ± 13.78 0.542
  Diastolic ABP 87.5 ± 12.01 86.1 ± 11.44 0.582
Notes: *Defined as central obesity (waist circumference .40 inches in non-Asian males, .35 inches in Asian males or non-Asian females, .31 inches in Asian females) and 
at least one of the following: fasting plasma glucose $100 mg/dL; and/or HDL , 40 mg/dL for males, ,50 mg/dL for females; and/or fasting triglycerides $150 mg/dL.
Abbreviations: ABPM, ambulatory blood pressure monitoring; sD, standard deviation; MssBP, mean sitting systolic blood pressure; MsDBP, mean sitting diastolic blood 
pressure; ABP, ambulatory blood pressure; HcTZ, hydrochlorothiazide.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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MSDBP were 168.8 ± 6.9/98.4 ±  8.6  mmHg  and 
170.5 ± 10.2/98.3 ± 9.0 mmHg in the valsartan/amlodipine/
HCTZ group and losartan/HCTZ group,   respectively. 
Least-squares mean ± SEM reductions of MSSBP/MSDBP 
at week 6 were -31.2 ± 2.8/-14.3 ± 1.9 mmHg and 
-30.8 ± 2.4/-11.0 ± 1.7 mmHg in the valsartan/  amlodipine/
HCTZ group and losartan/HCTZ group, respectively 
(P = 0.93/P = 0.194).
safety
Full safety results for the overall population have been reported 
previously.15 In the ABPM substudy population, 12/36 (33%) 
patients in the valsartan/amlodipine/HCTZ group and 18/48 
(38%) patients in the losartan/HCTZ group had at least one 
adverse event by week 6. The most   commonly reported 
adverse events (valsartan/amlodipine/HCTZ, losartan/HCTZ) 
were: dizziness (1 [3%], 3 [6%]), back pain (2 [6%], 1 [2%]), 
and pain in extremity (2 [6%], 0 [0%]). One patient in each 
group had an adverse event of hypotension.
Discussion
In the EXALT ABPM sub-study, ABP reductions were 
significantly greater with the valsartan/amlodipine/HCTZ 
combination than with the losartan/HCTZ combination. 
These results were consistent with the clinic BP findings 
of the main study, which was designed to investigate 
whether triple-combination therapy with moderate doses 
of an ARB and a CCB with a diuretic was comparable or 
superior to dual-combination therapy with the maximal 
available fixed combination dose of an ARB with a diuretic.15 
Thus, the observed differences in ABPM lowering were 
attributable to the combination of moderate doses of a CCB 
with an ARB + diuretic versus the maximal dose of an 
ARB + diuretic.
In contrast to the clinic BP findings of the main study,15 
among the patients in the ABPM substudy, there was no 
significant difference in clinic BP results between the 
two treatment groups. This observation could have been due 
to the small number of patients in the substudy. For the main 
−
2
2
.
0
 
−
2
2
.
2
 
−
2
1
.
9
 
−
2
1
.
5
 
−
1
3
.
3
−
1
3
.
3
−
1
3
.
0
 
−
1
3
.
5
 
−
1
7
.
4
 
−
1
6
.
2
 
−
1
8
.
1
 
−
1
7
.
0
 
−
8
.
1
 
−
7
.
4
 
−
8
.
6
 
−
7
.
7
 
−25
−20
−15
−10
−5
0
24-h
mean
Nighttime
(10 pm–6 am)
Daytime
(6 am–10 pm)
Last 4 h
dosing
24-h
mean
Nighttime
(10 pm–6 am)
Daytime
(6 am–10 pm)
Last 4 h
dosing
L
e
a
s
t
-
s
q
u
a
r
e
s
 
m
e
a
n
 
r
e
d
u
c
t
i
o
n
 
f
r
o
m
 
b
a
s
e
l
i
n
e
 
(
m
m
H
g
)
 
Valsartan/Amlodipine/HCTZ group (n = 36) Losartan/HCTZ group (n = 48)
Change in systolic ABP Change in diastolic ABP
−4.68*   −3.74  −4.47 
−5.27*  −5.90*  −4.34*  −5.82* 
−6.05*
Figure 2 LsM change from baseline to week 6 in ABP. changes were evaluated for the 24-hour mean values, the average of nighttime values (from 10 pm to 6 am), the 
average of daytime values (from 6 am to 10 pm), and the average values during the last 4 hours before the next dose of study medication.
Notes: Least-square mean differences between treatment groups are shown below the bars. *P , 0.05 by AncOVA with baseline ABP and treatment regimen as 
explanatory variables.
Abbreviations: ABP, ambulatory blood pressure; HcTZ, hydrochlorothiazide; AncOVA, analysis of covariance; LsM, least squares mean.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
706
Duprez et al
study, a sample size of at least 460 patients was projected to 
provide adequate power to detect a 5 mmHg difference in 
clinic BP between treatment groups. Only 84 patients were 
evaluable in the ABPM substudy; thus, treatment differences 
using clinic BP measures were not observed. These findings 
provide additional support for previous evidence that ABPM 
is a more sensitive measure than clinic BP to evaluate the 
BP-lowering efficacy of treatment.3
In addition to its increased sensitivity for changes in 
BP control, ABPM can be used to assess the BP-lowering 
efficacy of a treatment over the entire dosing interval 
and circadian patterns of BP control.17 In this analysis, 
significant treatment differences were seen not only for 
24-hour mean ABP, but also for nighttime ABP (10 pm to 
6 am), and ABP load (percentage of readings .140 mmHg 
[systolic] or .90 mmHg [diastolic]). The differences 
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between treatment groups in nighttime ABP were more 
pronounced than the differences in daytime ABP, which 
shows that triple-therapy combination provides even greater 
control at nighttime. Diminished nighttime decline in ABP 
has been shown to predict cardiovascular events18–20 and 
cardiovascular mortality.4,21 Similarly, ABP load has been 
reported to predict end-organ damage in patients with 
systolic hypertension.5,6
Two other recent reports described the effects of 
triple-therapy or dual-therapy combinations of an ARB, 
CCB, and diuretic on ABP endpoints in 283 patients22 
and 380 patients,23 respectively. In those studies, the full-
dose triple-therapy combinations (valsartan/amlodipine/
HCTZ 320/10/25 mg or olmesartan/amlodipine/HCTZ 
40/10/25 mg) lowered 24-hour, nighttime, and daytime 
ABP significantly more effectively than any dual-therapy 
combination at the same doses. The authors of the present 
paper compared lower doses of the ARB and CCB in the 
triple-therapy combination (valsartan/amlodipine/HCTZ 
160/5/25 mg) to dual therapy with full-dose losartan with 
HCTZ (100/25 mg). Although comparing the findings of 
the present study to the other   studies is limited by differ-
ences in study populations and study designs, the treatment 
difference of 5.4 mmHg in favor of the triple-therapy 
combination for the reduction of 24-hour mean systolic 
ABP in this study was similar to the 6.4 mmHg difference 
between the full-dose triple-therapy combinations and 
the ARB/HCTZ dual-therapy combinations in each of the 
previous studies.22,23
The main limitation of this analysis is the small number 
of patients in the ABPM substudy. Because of the small 
sample size, it was not possible to perform subgroup analyses 
of triple versus dual therapy within different subgroups 
(eg, gender, age, race, hypertension severity): future studies 
in these subgroups would be helpful. Another potential 
limitation is that postbaseline ABP evaluation was done 
only at week 6, which provided a single point estimate of 
the effects of study treatment on ABP.
Despite these limitations, the findings show that using 
ABPM, initiating treatment with a combination of moderate 
doses of an ARB, and a CCB with HCTZ lowers BP more 
effectively than a maximal dose of an ARB with HCTZ. 
These results support both the efficacy of combining lower 
doses of multiple antihypertensive agents and the use of ABP 
instead of clinic BP as a better measure of treatment efficacy 
in hypertension.
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